The acquisitions strengthen Eli Lilly’s strategy of investing in vaccine and prevention technologies aimed at reducing long-term disease risks tied to infections, including neurological disorders, cancer and antimicrobial-resistant bacterial diseases.“For 150 years, Lilly has advanced medicines to address the world’s most pressing health challenges,” the company said, adding that infectious diseases remain a major source of global morbidity and long-term health complications.Eli Lilly Targets Long-Term Disease PreventionDaniel Skovronsky, Lilly’s chief scientific and product officer and president of Lilly Research Laboratories, said the acquisitions support a broader prevention-focused strategy.“These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Skovronsky said. “Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility.”Deal Terms And Vaccine Pipeline ExpansionCurevo’s lead candidate, amezosvatein, is a shingles vaccine currently in Phase 2 development. Eli Lilly said the vaccine showed comparable immune responses to the current standard of care while reducing side effects such as fatigue, chills and injection-site pain by more than half. Eli Lilly said Curevo shareholders could receive up to $1.5 billion in cash tied to upfront and milestone payments.LimmaTech Biologics develops vaccines targeting drug-resistant bacterial pathogens, including Staphylococcus aureus, Neisseria gonorrhoeae and Chlamydia trachomatis. Eli Lilly said the acquisition could total up to $780 million.Vaccine Company is developing nanoparticle-based vaccine technologies, including an Epstein-Barr Virus vaccine candidate. Eli Lilly said the deal could reach $1.55 billion in milestone-based payments.The transactions remain subject to customary closing conditions and regulatory approvals.LLY Technical Analysis: Bullish Trend Above Key Moving AveragesEli Lilly’s stock has shown strong performance over the past year, with a 12-month gain of 46.85%. The current price of $1079.40 is significantly above key moving averages, including 10.6% above the 20-day simple moving average (SMA) and 16.1% above the 200-day SMA, indicating a bullish trend.